This article is more than 5 years old. Information may no longer be current.
Sanofi, Eli Lilly settle patent litigation over diabetes medication
Click Here to Manage Email Alerts
Sanofi and Eli Lilly have announced a settlement agreement resolving litigation regarding the former’s patents on the diabetes medication Lantus SoloStar (insulin glargine), allowing Lilly to sell their own version of the pen-like injector in the United States.
As part of the agreement, Lilly – and its alliance partner, Boehringer Ingelheim – will begin selling its copy of the French drug maker’s injectable basal insulin product, Basaglar, in the U.S. on Dec. 15, 2016, pending FDA approval.
According to Lilly, Sanofi has granted them a royalty-bearing license to manufacture and sell Basaglar globally in its Kwikpen dosing device.
In a company press release, Sanofi said Lilly will pay royalties in exchange for a license on certain Sanofi patents. However, the agreement does not include Sanofi’s Lantus vial, Toujeo injectable insulin glargine or combination products.
All remaining settlement details are confidential, according to both companies.
The FDA tentatively approved Basaglar in August 2014. Following the settlement, Lilly officials said they now plan to request final approval.
For additional information, visit:
http://lilly.mediaroom.com/index.php?s=9042&item=137467